Lab
Poplar Healthcare, PLLC
Poplar Healthcare, PLLC was paid $17.51M by Medicaid between Jan 2018 and Jun 2024, across 57 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 31% of everything it billed.
33Billing provider infoPOPLAR HEALTHCARE, PLLC
MEMPHIS, TN 38125
MEMPHIS, TN 38125
33aNPI1346271251assigned 07/06/2006
33bProvider typeClinical Medical Laboratory
28Total paid$17.51M
24GClaims549,907
24DCodes billed57
24AFirst – last monthJan 2018 – Jun 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Tennessee
Rank by total paid#9 of 70
Median peer was paid$141K
This provider vs. median124×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,657 | $2.53M | |
| 2019 | 71,107 | $2.44M | |
| 2020 | 81,744 | $3.03M | |
| 2021 | 123,599 | $4.06M | |
| 2022 | 92,339 | $2.91M | |
| 2023 | 75,332 | $1.82M | |
| 2024incomplete | 27,129 | $714K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 31% | 120,614 | 104,874 | $5.39M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 20% | 61,009 | 50,089 | $3.44M |
| 87507 | 6.4% | 7,667 | 6,461 | $1.12M | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.8% | 39,014 | 35,901 | $844K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.8% | 39,334 | 36,193 | $842K |
| 88312 | 4.4% | 31,310 | 28,423 | $769K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.4% | 42,250 | 35,625 | $766K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 3.2% | 38,074 | 34,699 | $560K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.0% | 26,119 | 24,194 | $533K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.8% | 2,422 | 2,294 | $497K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.5% | 23,134 | 21,042 | $432K |
| 87481 | 2.0% | 17,685 | 12,542 | $357K |
45 more codes
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.0% | 11,830 | $343K |
| 81513 | 1.6% | 7,432 | $280K | |
| 88342 | 1.1% | 7,726 | $193K | |
| 88313 | <1% | 10,143 | $174K | |
| 87653 | <1% | 7,602 | $168K | |
| 87511 | <1% | 5,586 | $109K | |
| 87563 | <1% | 7,727 | $108K | |
| 88112 | <1% | 6,539 | $105K | |
| 88141 | <1% | 6,746 | $78K | |
| 87640 | <1% | 3,684 | $53K | |
| 87486 | <1% | 2,412 | $44K | |
| 87581 | <1% | 2,410 | $44K | |
| 87480 | <1% | 4,020 | $39K | |
| 87510 | <1% | 3,966 | $36K | |
| 87660 | <1% | 3,469 | $32K | |
| 88341 | <1% | 483 | $26K | |
| 88142 | <1% | 1,806 | $21K | |
| 88120 | <1% | 273 | $21K | |
| 87529 | <1% | 1,053 | $14K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 143 | $13K |
| 88304 | <1% | 673 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 427 | $11K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 347 | $11K |
| 88377 | <1% | 110 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,094 | $4K |
| 88184 | <1% | 79 | $3K | |
| 83993 | <1% | 590 | $3K | |
| 88185 | <1% | 80 | $2K | |
| 87505 | <1% | 120 | $2K | |
| 88302 | <1% | 85 | $2K | |
| 82653 | <1% | 332 | $2K | |
| 87641 | <1% | 76 | $1K | |
| 87500 | <1% | 76 | $1K | |
| 87625 | <1% | 116 | $762.89 | |
| 88307 | <1% | 13 | $674.46 | |
| 88189 | <1% | 80 | $573.70 | |
| 88300 | <1% | 49 | $469.49 | |
| 87338 | <1% | 156 | $467.24 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,027 | $445.13 |
| 87324 | <1% | 61 | $314.03 | |
| 87088 | <1% | 74 | $281.61 | |
| 87186 | <1% | 45 | $256.51 | |
| 83631 | <1% | 42 | $186.85 | |
| 0753T | <1% | 440 | $0.04 | |
| 0756T | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialELDREDGE, BRANDON (CHIEF FINANCIAL OFFICER)